Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD)[@CIT0001] and asthma[@CIT0002] are common chronic respiratory conditions that are associated with significant morbidity, mortality and high healthcare costs.[@CIT0003] COPD claimed 3 million lives globally in 2016, making it the fourth leading cause of death and by 2030 it is expected to be the third leading cause.[@CIT0004] Although there was a significant reduction in asthma deaths in Australia from 964 (standardised mortality rate 5.6/100,000/year) in 1989 following the publication of the Australian Asthma Management Plan[@CIT0005] to 447 (1.5/100,000/year) in 2008,[@CIT0006] there has been no further improvement either in Australia or internationally over the last decade.[@CIT0007]

Asthma and COPD have similar clinical manifestations; however, their underlying pathophysiological mechanisms and epidemiological features are distinct.[@CIT0008] This leads to difficulty in diagnosis when patients present with features of both conditions. It has been proposed that these patients have "asthma-COPD overlap (ACO)".[@CIT0009] ACO has been defined by the Global Initiative for Asthma (GINA) and Global initiative for Obstructive Lung Disease (GOLD) as persistent airflow limitation with several key characteristics typical of both asthma and COPD in the absence of an alternative diagnosis. Epidemiological studies have reported varying prevalence rates for ACO (ranging from 15% to 55%) depending on age, sex and criteria used to define ACO in the sample.[@CIT0010]--[@CIT0017] Definitions and diagnostic criteria are yet to be standardised for this relatively new condition. Better characterisation and understanding of ACO should be fundamental to improving the diagnosis, management and prognosis of patients presenting with features of mixed airways disease.

A global expert panel[@CIT0018] defined ACO as the presence of three major criteria: (1) significant smoking exposure, (2) chronic airflow limitation and (3) documented history of asthma, and at least one minor criterion out of (1) documented history of atopy or allergic rhinitis, (2) improvement of Forced Expiratory Volume in 1 second (FEV~1~) ≥ 12% and ≥200 mL or (3) elevated blood eosinophils. The National Asthma Council and Lung Foundation Australia have issued a joint information paper for health professionals that highlighted the age of onset, history, pattern of symptoms, lung function, long-term disease trajectory and chest X-ray findings of patients with ACO.[@CIT0019]

However, there have been no published primary care studies in Australia comparing clinical characteristics or symptoms between patients with COPD alone and ACO. Better understanding of characteristics and differences between COPD and ACO may help clinicians identify patients with ACO and facilitate more appropriate management.

Objective {#S0001-S2001}
---------

The primary objective of this study was to compare and contrast the demographic and clinical characteristics, dyspnoea, quality of life, comorbidities, treatment and lung function between primary care patients with COPD alone or ACO.

Methods {#S0002}
=======

We used baseline data from the RADICALS (Review of Airway Dysfunction and Interdisciplinary Community-based care of Adult Long-term Smokers) trial to compare the two groups.[@CIT0020] RADICALS was a cluster randomised controlled trial evaluating an interdisciplinary community-based model of care in adult long-term smokers aimed at reducing the burden of smoking and COPD in Australian primary care. The study recruited patients aged 40 years or older, current or ex-smokers with a history of at least 10 pack-years of smoking, with or without an existing diagnosis of COPD, and who had at least two visits to the general practice in the previous year. The primary endpoint for the trial was changes in COPD-related quality of life as assessed by the St George's Respiratory Questionnaire (SGRQ).[@CIT0021]

Detailed descriptions of baseline characteristics in the whole group have been published previously.[@CIT0022] COPD was confirmed by pre- and post-bronchodilator spirometry conducted in accordance with the American Thoracic Society/European Respiratory Society guidelines.[@CIT0023] Following the Lung Foundation Australia's COPD-X guidelines,[@CIT0024] COPD was defined as FEV~1~ \< 80% predicted and FEV~1~/FVC \< 0.7. ACO was defined for this analysis by acute bronchodilator reversibility, a key feature included in the definitions of ACO.[@CIT0018],[@CIT0025]

Secondary endpoints included the COPD Assessment Test (CAT)[@CIT0026] and the modified Medical Research Council (mMRC) dyspnoea scale.[@CIT0027] Demographic characteristics examined included age, sex, education, employment, marital status, living arrangements and household income. Clinical characteristics included comorbidities, the Charlson Comorbidity Index[@CIT0028] and medications, which were classified into those for respiratory and non-respiratory indications. Inhaled respiratory medications included short-acting beta-agonists, short-acting antimuscarinics, long-acting beta-agonists (LABA), long-acting antimuscarinics (LAMA) and inhaled corticosteroids (ICS), alone or in combinations.

The RADICALS trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614001155684). The methods were performed in accordance with relevant guidelines and regulations including the Declaration of Helsinki and approved by Monash University's Human Research Ethics Committee. Written informed consent was provided by all participants. An appropriate research question/proposal that has received ethics approval would be considered by the investigators for sharing of individual de-identified participant data related to the analysis reported in this paper. The study protocol has already been published[@CIT0020] and the data codebook could be provided on request. The data would be made available on a secure Cloud server from the date of publication for 2 years.

Statistical Analysis {#S0002-S2001}
--------------------

Statistical analyses were performed using SPSS (ver 25, IBM, Armonk, NY) or Stata (ver 14, StataCorp, College Station, TX). Baseline characteristics were described using numbers (proportions), means ± standard deviations (SD), or medians and interquartile ranges \[IQR\], depending on the type and distribution of data. Associations with ACO were assessed using *χ*^2^ tests. Differences between group means were assessed using Student's *t*-tests. As distributional assumptions were not satisfied, mMRC dyspnoea scores and numbers of conditions or medications were compared using Mann--Whitney *U*-tests. Adjustments were made to allow for clustering by practice (within practice correlations). A *P*-value \< 0.05 was considered to be statistically significant.

Results {#S0003}
=======

Baseline interviews were conducted among 1050 patients from 41 practices. Case finding and spirometry identified 142 patients with a new diagnosis of COPD. Of 245 patients currently managed for COPD, 130 satisfied a spirometry-based definition.[@CIT0022] From this total of 272 participants with COPD, 60 (22%) were identified to have spirometric features consistent with ACO.

[Table 1](#T0001){ref-type="table"} shows the demographic characteristics of patients with COPD alone (n = 212 from 35 practices) and those with ACO (n=60 from 25 practices). Age was similar across groups. Females and non-concession cardholders had greater prevalence of ACO than COPD, but none of the differences reached statistical significance. Most patients were still smoking daily. There was no significant difference in the duration of smoking, nor were there any differences in marital status, education, employment status, living arrangements or annual household income (data not shown).Table 1Demographic Characteristics Of Patients With COPD Alone Or Asthma COPD OverlapCharacteristicCOPD Alone (n=212)ACO (n=60)P-valueAgeMean (±SD) Years64.8 (±10.6)64.1 (±11.5)0.73GenderMale, n (%)130 (63.7)32 (53.3)Female74 (36.3)28 (46.7)0.15Current smoking (n=264)Daily, n (%)118 (57.8)37 (61.7)Occasional6 (2.9)1 (1.7)Former smoker79 (38.7)21 (35.0)Never smoked1 (0.5)1 (1.7)0.61History of smokingYears40.6 (±11.9)39.2 (±11.3)0.37Marital status (n=260)Married/De-facto94 (46.8)25 (42.4)Never married/Single40 (19.9)10 (16.9)Separated/Divorced48 (23.9)19 (32.2)Widowed19 (9.5)5 (8.5)0.46Highest Education (n=261)Primary Education or less15 (7.4)3 (5.1)High School95 (47.0)31 (52.5)Technical or Further education52 (25.7)18 (30.5)University Education40 (19.8)7 (11.9)0.49Healthcare Concession Card (n=260)Yes147 (73.1)35 (59.3)0.08[^1]

The clinical characteristics of patients with ACO showed no significant differences compared to those of COPD alone ([Table 2](#T0002){ref-type="table"}). However, the patients with ACO were slightly more likely to have a history of eczema (11.7%) as compared to COPD alone (4.4%). Neither were there any meaningful differences in the proportions of patients who had been prescribed any of the classes or combinations of inhaled respiratory medications nor numbers of non-respiratory medications.Table 2Clinical Characteristics And Treatment Of Patients With COPD Alone Or Asthma COPD OverlapCOPD Alone (n=203)ACO (n=60)P-ValueNumber of comorbid conditionsMedian \[IQR\]4 \[2--6\]3 \[2--6\]0.62Charlson comorbidity index(n=93)1 \[1--2\]1 \[1--2\]0.72History of eczeman (%) (n=203)9 (4.4%)7 (11.7%)0.07History of allergic rhinitis5 (2.5%)1 (1.7%)0.71History of chronic sinusitis3 (1.5%)3 (5.0%)0.26Short-acting beta-agonists77 (37.9%)20 (33.3%)0.53Short-acting antimuscarinics6 (3.0%)1 (1.7%)0.59Long-acting beta agonists (LABA)78 (38.4%)25 (41.7%)0.70Long-acting antimuscarinics (LAMA)89 (43.8%)23 (38.3%)0.40Inhaled corticosteroids (ICS)80 (39.4%)26 (43.3%)0.64ICS + LABA72 (35.5%)25 (41.7%)0.45LABA + LAMA56 (27.6%)16 (26.7%)0.89ICS + LABA + LAMA (Triple therapy)50 (24.6%)16 (26.7%)0.75Number of non-respiratory medicationsMedian \[IQR\]3 \[1--6\]3.5 \[2--7\]0.21[^2]

Lung function, symptoms and quality of life in the two groups are compared in [Table 3](#T0003){ref-type="table"}. Mean pre-bronchodilator FEV~1~ and FVC were both significantly lower in patients with ACO than in those with COPD alone. However, there were no significant differences in post-bronchodilator spirometry, symptoms or quality of life. Most of the patients reported only mild dyspnoea on exertion.Table 3Lung Function, Quality Of Life And Dyspnoea In Patients With COPD Alone Or Asthma COPD OverlapMean (±SD)COPD Alone (n=204)ACO (n=60)P-ValuePre-bronchodilator spirometry FEV~1~ (%predicted)67.5 (±20.1)58.4 (±14.3)\<0.001FVC (%predicted)91.9 (±17.2)82.1 (±16.9)\<0.001FEV~1~/FVC0.56 (±0.12)0.55 (±0.10)0.36Post-bronchodilator spirometry FEV~1~ (%predicted)70.0 (±20.9)69.9 (±15.1)0.96FVC (%predicted)94.2 (±17.7)94.7 (±15.4)0.80FEV~1~/FVC0.57 (±0.12)0.57 (±0.09)0.91Quality of Life/Impact of COPD on life St George's Respiratory Questionnaire31.4 (±17.5)33.2 (±19.7)0.56COPD Assessment Test13.0 (±7.5)13.5 (±8.3)0.68Median \[IQR\]Dyspnoea Modified MRC scale1 \[0--2\]1 \[0--2\]0.56[^3]

Discussion {#S0004}
==========

This is the first study to characterise patients with ACO in Australian primary care. We found that 23% of the patients diagnosed with COPD through spirometry met criteria for ACO. Clearly, the prevalence of ACO is dependent on the definition used. In a population-based study from the Netherlands,[@CIT0029] Bonten et al concluded that differences in prevalence, patient characteristics and exacerbations reported in the literature were due to limited agreement on the definition of ACO, and therefore a consensus definition of ACO was urgently needed.

In our study we followed the definition for COPD recommended in the COPD-X guidelines and added the reversibility criteria as proposed by Sin et al.[@CIT0018] In the present analysis, no differences in demographic or clinical characteristics were observed between those with ACO and COPD. However, the pre-bronchodilator values of FEV~1~ and FVC (both absolute and %predicted values) were significantly lower in the ACO group.

Some previous studies[@CIT0030],[@CIT0031] have reported that patients with ACO had significantly lower health-related quality of life as measured by the SGRQ. In the Latin-American Pulmonary Obstruction Investigation Project (PLATINO) study,[@CIT0032] only 91 (1.8%) out of 5044 subjects were classified as having ACO on the basis of post-bronchodilator FEV~1~/FVC \< 0.7, acute bronchodilator reversibility and wheezing in the last year. In PLATINO, this overlap phenotype was associated with worse general health status, more hospitalizations and exacerbations compared with the reference COPD group. In a post hoc analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study,[@CIT0033] the SGRQ total score was higher in patients with ACO defined by a history of asthma, as compared to COPD after adjusting for age, sex, baseline FEV~1~ and history of prior exacerbations. However, in our study, SGRQ score was related to sex and baseline FEV~1~, but not ACO (results not shown).

Previous studies comparing lung function between COPD and ACO have reported inconsistent results. The ACO group had the lowest post-bronchodilator lung function values in some studies,[@CIT0030],[@CIT0032],[@CIT0034] while in others, better lung function has been reported.[@CIT0010],[@CIT0035] In a cross-sectional study of 9104 individuals from Korea, subjects with ACO showed significantly lower pre-bronchodilator lung function (FEV~1~%predicted, FVC %predicted and FEV~1~/FVC) than either the asthma or the COPD group.[@CIT0036] Similar findings were also reported by PLATINO.[@CIT0032]

There are also some comparative lung function data from clinical studies. Kauppi et al[@CIT0010] studied 1855 patients discharged with a diagnosis of asthma, COPD or both from a Finnish hospital over 11 years. Compared to COPD, the overlap group had higher pre-bronchodilator (FVC %predicted) and post-bronchodilator (FEV~1~ and FVC %predicted) values but lower than the asthma group. Cosentino et al[@CIT0037] did a retrospective analysis of the COPDGene study, a multicentre prospective observational study including 10,191 patients from 21 clinical centres. ACO patients had a higher FEV~1~/FVC ratio, FEV~1~%predicted and FVC %predicted than COPD patients.

Many studies have reported that patients with ACO are younger than those with only COPD.[@CIT0010],[@CIT0017],[@CIT0030]--[@CIT0032] Sex differences have also been reported for ACO, with a higher prevalence among women (4.0%) than in men (2.2%),[@CIT0038] while others found a higher prevalence among men.[@CIT0017],[@CIT0039]

We found no statistically significant difference in the number of comorbidities nor the number of medications prescribed (respiratory and other) between the groups. While we did not find any significant difference in Charlson Comorbidity Index, these scores could only be calculated for a minority of patients because of missing data. In a subgroup analysis of the ECLIPSE study,[@CIT0033] it was found that the proportions of co-morbidities were higher in ACO patients (66%), compared with COPD patients (43%). However, both groups had similar prevalence of cardiovascular diseases. There were no significant differences between ACO and COPD in comorbidities other than rhinitis in an analysis of the British Optimum Patient Care Research Database.[@CIT0017]

Other studies reported that significantly more inhaled therapy, especially ICS in combination with LABA, were used by ACO patients than COPD.[@CIT0040],[@CIT0041] We found that 39% of the COPD patients received ICS, but 57% of the ACO patients did not receive ICS. We did not expect such a high proportion of ICS users among those with COPD, neither would we expect such a high proportion of patients with ACO not receiving ICS. We had no influence on the treatments given by the GPs, but these unexpected proportions highlight the need for more studies on ACO and specifically on the most appropriate treatment.

A strength of our study is that it was a real-life assessment recruiting heavy smokers newly diagnosed with COPD and those already being treated for COPD in multiple primary care clinics with a large number of GPs. Such clustering minimised the risk of contamination associated with the same practice staff treating all the patients and appropriate statistical adjustment for clustering was performed.

However, there were also some limitations in this study. Firstly, we had no group of patients with asthma alone, unlike other studies.[@CIT0017],[@CIT0032],[@CIT0035] An asthma group would have allowed us to compare ACO not only with COPD but also to patients with asthma alone. We did not have data on bronchial hyper-reactivity, eosinophil counts or atopy. These were however clearly beyond the scope of the general RADICALS trial.[@CIT0020]

An important limitation was the definition of ACO. We used the reversibility criteria proposed by Sin et al.[@CIT0018] An FEV~1~ or FVC improvement of ≥200 mL or 12% from baseline values is the criterion recommended by the American Thoracic Society (ATS) for significant bronchodilator response.[@CIT0042] However, we agree that this cut-off is not ideal to separate asthma from COPD. Indeed the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) has recommended in order to improve the diagnostic performance, the use of 15% and 400 mL as the cut-off for patients with only one spirometric measurement or the traditional 12% and 200 mL cut-off for those with multiple measurements.[@CIT0043] The majority of our patients had multiple measurements and therefore our definition was also in accordance with SEPAR. However, we agree that none of these cut-off values are perfect for clearly separating asthma and COPD.

Another limitation was that due to the relatively small number of ACO patients and non-smokers, this posthoc analysis was underpowered to detect some differences in secondary outcomes between the groups. We also accept that general practices that chose to participate in the trial might not be representative of all practices in Australia, so the findings should be generalised with caution. Finally, we had some missing data especially in comorbidities and medications.

Nonetheless, our findings have significant implications for the management of long-term smokers in primary care. The benefits may include further justification of spirometry, which would open the door to better targeted treatment, because of differences in the optimal treatment of the two conditions. The findings could also increase the proportion getting care in accordance with local guidelines such as the COPD-X.[@CIT0024] With the advent of precision medicine, there is now greater focus on "treatable traits" rather than diagnostic labels.[@CIT0044] The pulmonary treatable traits relevant to airways disease in these patients include airflow limitation, eosinophilic airway inflammation and chronic bronchitis, among others which can co-exist.

Conclusion {#S0005}
==========

In this study, which was the first to characterize ACO in a large group of smokers/former smokers and those managed as having COPD at general practices in Australia, we found that only the pre-bronchodilator lung function was lower in the ACO subpopulation. The ACO and COPD groups otherwise had similar demographic and clinical characteristics, dyspnoea and quality of life. The present study and the available literature highlight the importance of performing spirometry for accurate diagnosis in primary care. Larger-scale primary care-based studies focusing on ACO and treatable traits could bring further insights and help clinicians to better characterize, understand and treat this condition.
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[^1]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; ACO, asthma COPD overlap; SD, standard deviation.

[^2]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; ACO, asthma COPD overlap; IQR, interquartile range.

[^3]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; ACO, asthma COPD overlap; SD, standard deviation; IQR, interquartile range; MRC, Medical Research Council.
